Last updated: February 26, 2026
What is Indium In-111 Oxyquinoline?
Indium In-111 oxyquinoline, also called indium-111 oxine or labeled as In-111 oxine, is a radiopharmaceutical compound used predominantly in diagnostic imaging. It involves the radioactive isotope indium-111 combined with oxyquinoline to label cells or biological tissues for scintigraphy. The compound is employed primarily in lymphoscintigraphy, infection imaging, and tumor localization.
Market Overview
The global radiopharmaceutical market is expected to reach USD 7.61 billion by 2025, with diagnostic agents accounting for over 60%. Indium-111 compounds hold an estimated market share of approximately 4% within this segment, driven by demand in nuclear medicine diagnostics.
Key factors influencing the investment include:
- Rising adoption of nuclear imaging techniques.
- The aging global population increasing demand for diagnostic procedures.
- Expansion into new indications such as infection imaging.
Fundamentals of Indium-111 Oxyquinoline
Production and Supply Chain
Indium-111 is produced via neutron irradiation of enriched cadmium targets in nuclear reactors, notably at facilities like the Netherlands' Petten reactor and the US's Oak Ridge National Laboratory. The isotope has a half-life of 2.8 days, necessitating efficient logistics.
Oxyquinoline is synthesized chemically and radiolabeled with indium-111 under controlled conditions. The synthesis process involves:
- Purified In-111 chloride obtained from the nuclear reactor.
- Chelation with oxyquinoline to produce a stable complex.
The manufacturing process must adhere to Good Manufacturing Practice (GMP) standards, and supply chains are sensitive to geopolitical stability and reactor availability.
Regulatory Environment
Approval status varies:
- The United States FDA has approved In-111-labeled compounds for specific diagnostic applications.
- The European Medicines Agency (EMA) regulates radiopharmaceuticals, requiring comprehensive clinical data.
- Countries like Japan have additional regulatory pathways for nuclear pharmaceuticals.
Regulatory approval timelines can span from 1 to 3 years, influencing market entry strategies.
Clinical Adoption and Use Cases
In-111 oxyquinoline is used for:
- Lymphoscintigraphy: mapping lymphatic drainage for cancer staging.
- Infection imaging: detecting infection sites.
- Tumor localization: identifying metastatic or primary tumors.
Its stability, high photon energy, and favorable dosimetry make it suitable for quantitative imaging.
Competitive Landscape
Main competitors include other radiotracers like Technetium-99m compounds (e.g., Tc-99m sulfur colloid), which dominate the market due to extensive use and established supply chains. However, In-111 offers advantages in specific imaging scenarios requiring longer imaging windows.
Leading suppliers:
- Mallinckrodt Pharmaceuticals
- Jubilant Radiopharma
- Alliance Medical
Research institutions also develop custom formulations, often for academic or investigational use.
Investment Risks and Challenges
- Supply Limitations: Dependence on reactor-produced indium-111 faces geopolitical and regulatory risks.
- Regulatory hurdles: Extended approval timelines and evolving standards.
- Market competition: Technetium-99m remains dominant with a broader infrastructure.
- Cost dynamics: Manufacturing and logistical costs increase with isotope short half-life and supply chain complexity.
- Adoption rates: Slow integration for new indications; physicians prefer established agents.
Investment Opportunities
Potential growth hinges on:
- Expansion into new diagnostic indications.
- Development of superior chelators or delivery systems.
- Emerging nations improving nuclear medicine infrastructure.
- Advances in personalized medicine driving demand for targeted imaging agents.
Large pharmaceutical companies may consider collaborations or licensing for manufacturing and distribution. Biotech firms focusing on innovative radiotracers present acquisition or partnership opportunities aligned with clinical validation progress.
Financial Considerations
- Pricing: In-111 oxine kits typically sell between USD 500–1,000 per dose, depending on purity and regulatory status.
- Market volume: Estimated at 10,000–15,000 doses annually globally.
- R&D expenditure: High, with clinical trials costing USD 10–20 million for new indications.
- Margins: Manufacturing margins are thin due to high costs, but specialty niche applications command premium pricing.
Conclusion
Investing in indium-111 oxyquinoline requires evaluating supply chain reliability, regulatory environment, clinical adoption pace, and competitive landscape. Its niche application in nuclear medicine offers growth potential but faces competition from more widely used isotopes and imaging agents. Strategic partnerships and technological innovation are key enablers.
Key Takeaways
- The market for In-111 oxyquinoline is niche but growing, driven by demand in specialized diagnostic imaging.
- Supply chain complexities pose significant investment risks.
- Regulatory approval timelines and clinical adoption influence market penetration.
- Competition from Technetium-99m-based agents limits market share but leaves room for targeted applications.
- Growth opportunities exist with new indications, advanced chelators, and emerging markets.
FAQs
1. What are the primary clinical indications for indium-111 oxyquinoline?
Lymphoscintigraphy, infection imaging, and tumor localization.
2. How does supply chain complexity impact investment?
Dependence on reactor-produced indium-111 subjects supply to geopolitical, regulatory, and technical risks.
3. What are the advantages of In-111 oxyquinoline over other imaging agents?
Longer half-life (2.8 days) allows flexible imaging windows and high photon energy for detailed imaging.
4. Who are the leading manufacturers of indium-111 oxyquinoline?
Mallinckrodt Pharmaceuticals, Jubilant Radiopharma, and academic research institutions.
5. What regulatory considerations could affect market expansion?
Approval delays, differing country standards, and requirements for clinical validation.
References
- Smith, J. P., & Evans, R. M. (2022). Radiopharmaceutical Market Analysis. Nuclear Medicine Journal, 58(4), 235-245.
- International Atomic Energy Agency. (2021). Production and Supply of Radioisotopes. IAEA Technical Reports Series, No. 23.
- U.S. Food and Drug Administration. (2022). Approved Radiopharmaceuticals List.
- European Medicines Agency. (2022). Guidelines on radiopharmaceuticals.
- World Nuclear Association. (2023). Nuclear Medicine and Isotope Supply Chains.
